Vaccination history to consider:
-tetanus (Tdap)
-diphtheria (Tdap)
-pertussis (Tdap)
-HPV
-influenza
-hepatitis A
-hepatitis B
-meningococcal
-MMR
-varicella
-H. zoster
Laboratory studies:
-RUBEOLA, MUMPS, RUBELLA IGG ANTIBODIES (PAML | MMRG)
-VARICELLA-ZOSTER ANTIBODY, IgG (PAML | VZA)
-HEPATITIS A VIRUS ANTIBODY, TOTAL (PAML | HAVAB)
-HEPATITIS B SURFACE ANTIBODY (PAML | HBSAB)
Vaccines to consider in specific patient groups regardless of immunosuppressive drug use:
-Tdap (tetanus, diphtheria, pertussis)
-HPV (select populations)
-influenza
-pneumococcal
-hepatitis A
-hepatitis B
-meningococcal
Vaccines to consider if no plans to start immunosuppressive therapy in 4-12 weeks:
-MMR*
-Varicella*
-H. zoster (select populations)*
*live vaccines (avoid immunomodulators and TNF-inhibitor for 4-12w)
Adapted from:
Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am J astroenterol. 2010 Jun;105(6):1231-8. Epub 2010 Jan 26. Review. PubMed PMID: 20104218.
Additional information regarding zoster vaccination and immunosuppressive therapy
Zoster vaccination should be deferred for at least 1 month after discontinuation of high dose corticosteroid therapy (≥20 mg/day of prednisone or equivalent. Zoster vaccination is not contraindicated by low-does of methotrexate (≤0.4 mg/Kg/week), azathioprine (≤3 mg/Kg/day), 6-mercaptopurine (≤1.5 mg/Kg/day).
|